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EFFECT OF MALARIA ON HIV VIRAL LOAD AND MATERNAL OUTCOMES IN HIV-
POSITIVE PREGNANT WOMEN OF ACCRA, GHANA   
Jana Halfon, Elizabeth Levey, Margaret Lartey, Richard Adanu, Michael Ntimi, Larysa Aleksenko, 
Kwamena Sagoe, Patrick Kumi, Michael Cappello, and Elijah Paintsil (Sponsored by Elijah Paintsil, Yale 
School of Medicine, through the Doris Duke Charitable Foundation)  
 HIV-1 positive pregnant women co-infected with malaria face increased risk of Mother-to-child-
transmission (MTCT) of HIV. Placental malaria has been implicated, whether through an increase in 
placental or peripheral HIV viral load or a disruption of placental architecture. But the mechanism is not 
well understood. There are no studies in West Africa, where HIV and malaria co-infection is prevalent.  
  We determined whether reported malaria infection in HIV-1 positive pregnant women affects 
either peripheral or placental HIV viral load. Establishing how malaria affects HIV-positive pregnancies in 
this population is of public health significance.  
 130 HIV-positive pregnant women in their third trimester were recruited at the Korle-Bu Teaching 
Hospital in Accra, Ghana from 2007 to 2009 and followed prospectively until delivery. Of 130 recruited, 
65 delivered at Korle-Bu. HIV-1 RNA concentration of peripheral and placental blood samples were 
measured using Amplicor HIV-1 Monitor version 1.5. Giemsa-stained peripheral and placental thick blood 
films were analyzed for malaria parasitemia. Periumbilical and peripheral full-thickness placental tissue 
biopsies were fixed, stained with Giemsa and H&E, and assessed by a pathologist blinded to subject data. 
 The overall mean peripheral and placental HIV-1 viral loads were 5045 copies/ml (SD 16014) and 
3389 copies/ml (SD 10679), respectively. No significant effect was seen between subjects reporting and not 
reporting malaria during pregnancy. Significance was seen in the effect of 2 or more doses of intermittent 
preventative treatment on reducing incidence of malaria (p<0.0001) and in the effect of combination 
antiretroviral therapy in reducing HIV viral load compared to single-dose NVP at delivery (p=0.05). 
 The low mean HIV-1 viral loads in this population may be responsible for the low rate MTCT at 
Korle-Bu (0.3 percent, unpublished data). The low rate of transmission warrants further research on the 
local placental factors influencing transmission. Aggressive antimalarial and antiretroviral therapies are 
having a significant impact on reducing risk of developing clinical malaria and risks of MTCT of HIV, but 
better widespread access to care is still needed.  
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“In much of the world, the most dangerous thing a woman can do is become pregnant.”  
-- Nicholas Kristof, Half the Sky 
 
I.       INTRODUCTION 
 Maternal morbidity and mortality continue to be one of the most important global 
health issues, particularly in sub-Saharan Africa, home to half of all maternal deaths. 
According to the World Health Organization (WHO), 19 of the 20 countries ranked 
highest in maternal mortality ratios are in sub-Saharan Africa, where the maternal 
mortality rate averages between 920 to 1050 per 100,000 live births.1,2 In underdeveloped 
nations, maternal mortality rates have changed very little in the past 15 years and only 
about 33% of all maternal deaths are prevented. 1 In addition, for every woman who dies 
from obstetric causes, close to 20 more suffer injury, infection or disease – nearly 10 
million women each year. 2 But women are not the only population that suffers from high 
maternal death rates. Motherless children in the developing world are ten times more 
likely to die within the first two years of life. 2 Social development and well-being also 
suffer. The old African saying, “If you take all the men out of a village, nothing will 
change; if you take all the women out, the village will not survive,” applies. Women are 
the backbone of society in sub-Saharan Africa, rearing the children, managing the 
household, feeding the village. Many believe that the women of the developing world 
could play a major role in ending the cycle of poverty. 49 It is, therefore, of paramount 
importance to reduce maternal morbidity and mortality on the African continent -- for  
women, children, and sustainability of most African society.    




complications that account for over 70% of all maternal morbidity. 2 Hemorrhage 
continues to be the leading cause of mortality in the developing world, accounting for 
25% of all maternal deaths and up to 46% in some populations in West Africa. 4  Other 
causes include unsafe abortion (13%), eclampsia (12%), and obstructed labor (8%). A 
contributing factor to all these causes is, of course, access to care.  Better access to care 
would reduce deaths due to obstructed labor and eclampsia. Better resources could 
prevent so many fatal maternal hemorrhages.  
 Complications from infectious diseases during pregnancy is the second leading 
cause of maternal mortality in sub-Saharan Africa, accounting for nearly 15% of all 
maternal deaths. 4 The HIV pandemic continues to devastate this region, accounting for 
more than 70% of the world’s 40 million HIV-1 infected individuals. 7 And, like maternal 
mortality, this region accounts for a disproportionate number of the world’s HIV infected 
women, more than 80%.3  
 But though HIV is more notorious, malaria remains the most prevalent infectious 
disease affecting sub-Saharan Africa, and the most preventable. 2 In the adult population, 
women are at higher risk of malaria infection than men, and pregnant women are at more 
risk than non-pregnant women.20 Up to 66% of pregnant women in sub-Saharan Africa 
are infected with malaria.17 Thus, it is clear that both diseases significantly increase risk 
of maternal morbidity and mortality. But the effect of co-infection of the two diseases is 
still largely unknown.  
 A.  Overview of HIV in Pregnancy  
 Among pregnant women in sub-Saharan Africa, HIV prevalence rates can exceed 




child, specifically risk of mother-to-child transmission of the HIV virus. Mother-to-child 
transmission (MTCT) of HIV-1 continues to be a major global health issue, particularly 
in resource-limited countries such as those of sub-Saharan Africa. According to WHO 
statistics, an estimated 420,000 children were infected with HIV-1 in 2007, over 90% of 
which acquired via MTCT.2,4 HIV-infected infants have a higher risk of mortality than 
HIV-uninfected infants, but even uninfected infants who were exposed to HIV have a 
much higher risk of mortality than infants unexposed. 50 Reducing HIV infection in 
women  of the developing world is a complex, multifaceted undertaking with mixed 
success. Reducing risks of MTCT, on the other hand, can be highly successful.       
 Vertical transmission of HIV can occur in the prenatal, intrapartum, or postpartum 
period, but 50 to 80% of all transmissions are thought to occur during the time period 
near or during delivery.6, 51 Four main factors contribute to the risk of MTCT: 1) high 
maternal viral load of HIV RNA at time of delivery, 2) prolonged exposure to vaginal 
secretions during prolonged labor, 3) micro-disruption of placental integrity leading to 
exposure of fetus to maternal blood, and 4) transmission of HIV through breast milk 
(postpartum risk). 51 Interventions specifically targeted to each of these four factors have 
resulted in a dramatic reduction of MTCT.   
 Antiretroviral therapy has been the cornerstone of reducing maternal HIV RNA 
viral load, the single most important risk factor for MTCT.  In 1994, the Pediatric AIDS 
Clinical Trials Group (PACTG) protocol 076 demonstrated that a three-part regimen of 
zidovudine (AZT) given during the prenatal and antepartum period (as well as to the 
neonate) resulted in a 67% decrease in rate of MTCT. 51,52 The regimen begins at 14 to 34 




AZT during labor until delivery. 52 The goal is to reduce HIV RNA viral load to 
undetectable levels, or at minimum, to below 1000 copies/mL. Studies have shown that 
HIV RNA viral loads above this cut-off carry a 12-fold increased risk of vertical 
transmission. 53  
 For women with viral loads above 1000 copies/mL, elective caesarian sections have 
been shown to reduce MTCT of HIV. One study found that elective caesarians in women 
with >1000 copies/mL HIV RNA reduced the risk of MTCT by 90% compared to vaginal 
delivery or emergency caesarian. 53 Elective caesarian sections reduce the risk of 
prolonged labor through decreased exposure of fetus to vaginal secretions in the birth 
canal and decreased microtransmission of maternal blood during uterine contractions. 
Elective caesarians also reduce the risk of chorioamnionitis, a result of prolonged labor 
and another factor that may increase risk of MTCT of HIV. 51 
 Lastly, avoidance of breastfeeding eliminates the final risk of vertical transmission 
of HIV to the child. In the developed world, resources exist to supply new mothers who 
are HIV-positive with replacement formula, but in the developing world, these resources 
are scarce or financially infeasible. In Ghana, for example, the rate of exclusive 
breastfeeding in HIV-positive mothers is more than 40%, according to National Data.16 
The risk of transmitting HIV is weighed against the risk of malnutrition to or starvation 
of the infant, and in most developing nations, mothers risk HIV transmission in order to 
feed their new child. Though this topic is of great global significance, as avoidance of 
breastfeeding is the most preventable risk factor associated with MTCT, it will not be 
discussed here.  




developed world to less than 2%.3 In 2007, for example, only 67 children were born with 
HIV in the United States. 54 In the developing world, however, these interventions are 
difficult to achieve. Without intervention, rates of MTCT can reach 45%. 3 In sub-
Saharan Africa, for example, most pregnant women do not have access to prenatal care or 
counseling, and availability of highly active antiretroviral therapy (HAART) and 
caesarian delivery is limited. In areas with poor medical infrastructure, the three-part 
AZT regimen is too expensive and complex for implementation. Abbreviated anti-
retroviral regimens (ARV), on the other hand, have been more successful. These simpler 
and less expensive regimens have been shown to effectively reduce perinatal 
transmissions in resource-limited countries, significantly reducing the maternal viral load 
at delivery and therefore decreasing the risk of transmission. 5, 10-14  There are different 
permutations of regimens, but the most popular regimen is single-dose nevirapine (NVP) 
administered to the mother at the onset of labor and to the infant between 48-72 hours of 
life.2 This is not the most efficacious regimen, but it is the most cost-effective and 
feasible.50 Even then, it is estimated that only 33% of HIV-positive pregnant women 
receive any antiretroviral treatment, suggesting that increased access to care would have a 
profound effect on reducing MTCT worldwide.2  
 For areas that can afford it, first line therapy should be the additional administration 
of AZT and lamivudine from 28 weeks gestation to delivery and administration of a one-
week course of AZT to the infant. Lamivudine is added to reduce risk of HIV resistance 
to single-dose NVP. 50 Interestingly, HIV resistance does not appear to develop in 
subsequent pregnancies to single-dose NVP. In addition, the serious side effect of 




single-dose nevirapine during labor for prevention of mother to child transmission. 55 
Therefore, in the developing world, the benefit of using single-dose NVP far outweighs 
the risks.  
 It must also be mentioned that the first step to effectively reducing MTCT rates of 
HIV in any population is successful identification of pregnant women infected with HIV. 
This requires widespread and targeted prenatal testing and counseling to all pregnant 
women through prevention of mother-to-child transmission (PMTCT) programs. With 
effective programs and basic resources available to identified HIV-positive pregnant 
women, low rates of MTCT can be achieved, even in developing nations.54 Reducing risk 
factors to MTCT is the goal of every obstetrician, but recently a new risk factor has been 
identified that requires even further intervention, a risk factor that affects nearly 50 
million pregnant women on the African continent.2 That risk factor is malaria.  
 B. Overview of Malaria in Pregnancy 
 Though more focus has been placed on the HIV epidemic in sub-Saharan Africa, 
malaria is also recognized as a major global health issue. There were approximately 
881,000 malaria deaths in 2006, of which 91% were in Africa and 85% were children 
under 5 years of age.54 It is estimated that 10,000 women and 200,000 infants die each 
year as a result of malaria infection during pregnancy.54 Malaria, predominately the 
Plasmodium Falciparum species, can lead to severe maternal anemia during pregnancy, 
prematurity, and low birth weight, all of which contribute to infant mortality in sub-
Saharan Africa.54 Parasitemia peaks in the second trimester in both primigravidas and 
multigravidas, but the increased risk for pregnancy-associated malaria (PAM) persists for 




adversely affecting maternal and neonatal outcomes.    
    As stated before, pregnant women have the highest risk of developing malaria 
symptoms than any other adult population in sub-Saharan Africa.20 The reason for this is 
one of the unique features of the P. Falciparum malaria parasite.  Pregnancy selects 
for a specific population of parasites that express variant surface antigens (VSA).21  
These antigens adhere parasite-infected erythrocytes to chondroitin sulfate A (CSA) on 
the syncytiotrophoblast lining in the intervillous spaces of the placenta. The process of 
selection appears to be mediated by upregulated transcription of the var2csa gene. 21 
Adherence of parasite-infected erythrocytes to the placental lining leads to sequestration 
of leukocytes and a local inflammatory response, mediated by numerous cytokines and 
transcription factors, which will be discussed in the next section.22  This response can 
cause a disruption of placental architecture through local necrosis and syncytial 
degradation, and thus increase the risk of low-birth weight infants and possible fetal 
infection through breakdown of placental architecture.23 In an woman co-infected with 
HIV, this could possibly lead to microtransmission of maternal blood and entry of the 
virus.   
 Multiple studies have established that primigravidas are most at risk for malaria, 
with prevalence decreasing with increasing gravity.18,19 This is particularly true in malaria 
endemic countries, where women have an overall high immunity to malaria but have not 
developed specific antibodies to placental antigens until after their first pregnancy. The 
specific antibodies that develop are anti-VSA IgG immunoglobulins, and they have a 
protective effect against placental malaria during subsequent pregnancies. These 




reduce the risk of placental destruction. 21 In women with HIV, however, the reduced 
immunity may nullify the ability of the body to mount a response against the malaria 
parasite with anti-VSA IgG.33, 37 Interestingly, though, one recent study demonstrated that 
decreased levels of anti-VSA IgG were not associated with increased rates of clinical 
malaria or adverse maternal or infant outcomes in HIV-positive pregnant women, 
suggesting that several other mechanisms are at play.56  It seems clear that the interaction 
of malaria and HIV in co-infected pregnant women of sub-Saharan Africa is a complex 
process that is not entirely understood. 
 C.  Co-infection of HIV and Malaria in Pregnancy 
 In 2004, the WHO identified the prevention of malaria during pregnancy as a 
necessary tool in limiting maternal morbidity and mortality, particularly in HIV-positive 
individuals.2 The relationship between malaria and HIV was known beforehand, as 
several studies suggest that the interplay of the two infections seems to fuel the continued 
spread of both diseases. 24-30 HIV diminishes immunity thereby increasing the risk of 
malaria infection and the development of clinical malaria.24-26 Conversely, malaria has 
been show to increase HIV replication by activating the immune system by mechanisms 
similar to that found with vaccination and bacterial infections.27-30 The interplay of the 
two infectious diseases is also clearly seen during pregnancy.  One study demonstrated 
that HIV-1 positive pregnant women with peripheral malaria parasitemia had a two-fold 
higher HIV-1 plasma concentration than those HIV-positive pregnant women without 
malaria infection, when matched for initial HIV-1 viral load prior to infection.31 Other 
studies have demonstrated that co-infection of HIV and malaria is associated with an 




severe clinical disease compared to HIV-negative women. 37, 57. Placental and clinical 
malaria are more common in HIV-positive women, as are cases of infant and maternal 
death. 3,32 Recently, one additional parameter to the relationship between HIV and 
malaria in pregnancy has emerged: the potential risk of increasing MTCT.  
 The studies addressing the effect of malaria parasitemia on MTCT of HIV are, 
unfortunately, conflicting. The relationship was first identified in a study in Cameroon, 
where researchers found higher MTCT rates correlated with peak rainy seasons and with 
higher malaria transmission, suggesting an association between MTCT and higher rates 
of malaria during pregnancy.3 In Uganda, researchers found a significant increase in 
vertical HIV transmission associated with placental malaria. 34,35 However, a study in 
Mombasa, Kenya found no impact of placental malaria on MTCT.36 And lastly, a study 
in Kisumu, Kenya found an increased risk of MTCT only at high maternal parasitic 
densities compared with low parasitic densities.37 It has been proposed that significant 
discrepancies in methodological approaches to defining placental malaria in the Kenya 
studies can account for differences in outcome, but further studies are needed to confirm 
the role of malaria infection on HIV-1 vertical transmission and the mechanisms at play.  
 As discussed before, the interaction of malaria and HIV in pregnancy is complex, 
particularly at the level of the placenta.  Two main mechanisms have been proposed to 
explain the risk of placental malaria on MTCT of HIV: 1) increased HIV-1 viral load and 
2) disruption of placental architecture. The first involves the relationship between malaria 
infection and increased HIV RNA viral replication. Malarial infection results in a 
temporary increase in HIV RNA, an increase that will return to baseline after two months 




the last trimester could increase the risk of MTCT. 27,3,34   But a recent analysis by 
Brahmbhatt et al demonstrated that even after adjusting for maternal HIV viral load, 
placental malaria significantly increased the risk of MTCT, suggesting that increased 
HIV-1 viral concentration is not the sole mechanism for transmission.35  
 As mentioned previously, numerous cytokines and transcription factors mediate the 
local inflammatory response induced by sequestration of malaria in the placenta. Thus, it 
is possible that these factors could increase risk of MTCT by affecting the local placental 
environment, but little data is available and the studies that have been done are 
heterogenous. For example, in vitro studies of placental co-infection of HIV-1 and 
malaria have shown dose-dependent increases in local HIV-1 viral replication related to 
increased expression of TNF-alpha, a pro-inflammatory cytokine.32 However, another 
study found significantly reduced placental viral load compared to peripheral viral load 
among women with confirmed placental malaria, despite high levels of TNF-alpha.38 
Other studies have identified cytokines and factors induced by placental malaria presence 
with a more protective role against MTCT. One study suggests that placental malaria 
induces an upregulation of Th1 cytokine interferon-gamma in the intervillous blood 
mononuclear cells, which are known to reduce HIV replication.37 Leukemia inhibitory 
factor, which inhibits HIV replication, has been shown to be upregulated in women with 
placental malaria who do not transmit vertically.58 Studies have also shown that placental 
malaria can increase expression of macrophage inflammatory protein 1-Beta, which 
blocks HIV entry into cells.59 
 Thus, it appears that there is much controversy surrounding both proposed 




protect against MTCT or promote it? Are there cytokine or immune targets we can use to 
reduce the risk of vertical transmission of HIV? Can we identify specific placental 
immune factors in HIV-positive women who do not transmit? Do these same factors lead 
to adverse maternal outcomes? Understanding the mechanism by which HIV and malaria 
interact is incredibly important to answering these questions.   
 D. Prevention of Malaria in Pregnancy  
 Due to the high risk of maternal morbidity and infant mortality associated with 
pregnancy-associated malaria, the WHO identified malaria prevention as an essential 
component of prenatal care among all pregnant women in areas of stable P. falciparum 
transmission in Africa.39,40,54   Specifically, the WHO recommends use of insecticide-
treated bednets (ITN) and intermittent preventive treatment (IPT) during the course of the 
pregnancy. A curative dose of sulfadoxine-pyrimethamine (SP, Fansidar) administered 
twice at monthly intervals after the first trimester is the preferred method of prophylaxis 
for HIV-negative pregnant women.54 Though toxicity due to the sulfa component can 
occur, SP’s low cost, relative safety, ease of use, and efficacy outweigh adverse effects.39 
This two-dose regimen of IPT with sulfadoxine-pyrimethamine significantly reduced the 
incidence of placental malaria, LBW, and maternal anemia in women having a first or 
second pregnancy, even in areas where the prevalence of drug resistance was 19 to 26 
percent.41  
 For HIV-positive pregnant women, at least three or more doses of IPT is needed to 
prevent placental malaria.2 Numerous studies showed that while two doses of IPT with 
sulfadoxine-pyrimethamine was sufficient for HIV-negative women, more frequent 




dosing was significantly more effective than the two-dose regimen, as supported by a 
lower rate of placental malaria and an increase in birth weight, even in areas where the 
prevalence of drug resistance was as high as 39 percent. In HIV-negative women, 
monthly dosing did not improve outcomes over the two-dose regimen. 41  
 The more aggressive IPT regimens required for HIV-positive pregnant women 
supports the unique relationship between HIV and malaria co-infection during pregnancy, 
and the need to understand that relationship. In addition the scientific implications, 
understanding this relationship has significant policy implications towards the 
development of additional targeted, cost-effective strategies to reduce adverse maternal 
and infant outcomes.  Are more funding and efforts needed to prevent placental malaria 
infection in HIV-positive pregnant women or will more access to ARV treatments have a 
greater effect? In resource-limited environments, these are highly important questions 
that need to be answered.   
 E. Overview of Ghana 
 No previous study has investigated the relationship of HIV and malaria co-infection 
among pregnant women of Accra, Ghana. The Republic of Ghana is located in West 
Africa on the Coast of Guinea with a population of almost 24 million people. Accra is the 
capital of Ghana and has a population of about 3 million people. Compared to the rest of 
sub-Saharan Africa, HIV/AIDS rates in Ghana have remained relatively low and stable, 
rising from an estimated 2.4% in 1992 to 3.1% in 2004.16 In 2006, government-sponsored 
programs such as HIV testing and counseling sites and Prevention of Mother-to-Child 
Transmission (PMTCT) sites were increased in number throughout the country, including 




prevalence rate from 3.1% in 2004 to 1.9% in 2007. Among pregnant women, the 2007 
prevalence rate of HIV was slightly higher at 2.6% on average, 3.4% in urban locations, 
and there were 3,000 new infections among children in 2007.16 
 Ghana is holoendemic for malaria and has a stable rate of malaria transmission. It is 
perennial but peaks during the rainy and post-rainy season (June to August).  P. 
falciparum causes over 98% of all malaria infections.  
 The low prevalence rate of HIV but stable rate of malaria transmission make Ghana 
an interesting comparison study to the previous studies on malaria and MTCT in Eastern 
and Southern Africa, where HIV prevalence rates can reach up to 20% in some areas. 34-37 
The location of the study at the Korle-Bu Teaching Hospital is also an interesting 
comparison to the rural environments of most of the previous studies. Korle-Bu is a 
tertiary hospital and the largest teaching hospital in Western Africa. The hospital has 
1600 inpatient beds and several thousand outpatient visits a year. It also serves as the 
primary teaching hospital for University of Ghana Medical School. It is the referral center 
for all high-risk pregnancies, complicated pregnancies (including gestational diabetes, 
hypertension in pregnancy, or other comorbid diseases), and pregnancies in the third 
trimester in the Greater Accra and Eastern Region. Thus, it is the highest level of care 
available for the average Ghanaian woman who becomes pregnant in these areas.  
 
II.  STATEMENT OF PURPOSE 
 The first specific aim (1) was to determine the prevalence of P. falciparum 
parasitemia in peripheral blood of HIV-1 negative and positive pregnant women 




our hypothesis that HIV-1 positive women would have higher incidence of malaria 
parasitemia in comparison to HIV-1 negative women during pregnancy.  
The second specific aim was two-fold. One aspect of that aim (2a) was to compare 
the intensity of P. falciparum parasitemia in the peripheral blood and placenta of HIV-1 
positive women with or without clinical malaria at delivery. It was our hypothesis that 
there would be a high density of parasitemia in both blood and placenta, especially in 
women with clinical malaria. The other aspect of the second aim (2b) was to determine if 
placental P. falciparum parasitemia was associated with increased peripheral HIV-1 RNA 
concentration in HIV-1 positive women at delivery. It was our hypothesis that HIV-
positive women with increased intensity of placental parasitemia would also have higher 
HIV-1 RNA concentration in the peripheral blood.  
The third specific aim (3) was to determine the incidence of HIV-positive infants 
born to positive HIV-1 women with or without acute malaria infection. It was our 
hypothesis that HIV-positive women with placental malaria would have a higher 
incidence of HIV-1 positive infants.  
 
III. METHODS 
 The project was a two-year pilot study to investigate the specific aims listed above. 
Initial approval for the project was obtained through the Yale Institutional Review Board 
(IRB) and the Ghana IRB.  
 There were four parts to the pilot study design. Part I involved initial recruitment of 
both HIV-negative and HIV-positive subjects and the obtainment of demographic and 
specific disease-related information as reported by the subjects in a questionnaire.  Part I 




recruitment for thick blood smear, CD4 and viral load assessment. Part II involved the 
postpartum period - the obtainment of information relating to delivery, blood samples 
from the mother for thick smear and viral load assessment, and collection and processing 
of the placentas from HIV-positive subjects. Part III was placental histopathological 
analysis. Part IV was assessment of MTCT of HIV in the research population based on 
HIV-DNA testing of infant blood samples.   
 A. Background  
 The study was conducted at Korle-Bu Teaching Hospital in Accra, Ghana in five 
different departments. Initial recruitment of the HIV-positive pregnant women occurred 
at The Fevers Unit, the medical ward for patients with HIV, tuberculosis and other 
infectious diseases.  All patients who are treated at Korle-Bu and who test positive for 
HIV-1 are referred to this department, including all HIV-1 positive pregnant women. 
Further recruitment of HIV-positive pregnant women occurred in the Maternity Wards of 
the OB-GYN department. Recruitment of HIV-negative pregnant women occurred at the 
Antenatal Center  (ANC) of the OB-GYN department.   All pregnant women receiving 
care at Korle-Bu’s ANC are given a purple maternity booklet to carry with them at all 
times. This booklet serves as the obstetric chart - documenting routine prenatal care, 
medication use (including IPT administration), results of screening tests, and any medical 
complications that occur during the pregnancy.  Demographic and disease-specific 
information was obtained from this booklet. The National Health Scheme, Ghana’s 
government healthcare system, provides free medical care for all pregnant patients, 
including antiretroviral and antimalarial medications.    




participate in the Prevention of Mother to Child Transmission (PMTCT) program. 
Pregnant women are encouraged to obtain HIV testing and over 98% of pregnant women 
agree to be tested (data not presented). If women test positive for HIV, they are referred 
to the Fevers Unit to begin HIV care.  At the Fevers Unit, blood samples are taken to 
determine CD4 count.    
  B.  Consent 
 Two separate written consent forms were devised - one describing the procedure for 
HIV-negative subjects, one describing the procedure for HIV-positive subjects. The 
consent was written in English. If the subject did not speak English, a translator was 
employed to explain the details of the consent. All subjects received a written copy of the 
consent form and were asked to sign a separate form confirming that consent was 
obtained. If subjects were unable to write, they provided their fingerprint, a common 
practice among illiterate individuals in Ghana.  
  C. The Questionnaire 
 A brief questionnaire was designed to obtain basic information regarding obstetric 
history (past and present), socio-economic history, demographics, and disease-specific 
history of both HIV and malaria exposure. The questionnaire was written in English. As 
with the consent, if the subject did not speak English, a translator was employed.  
 D. Inclusion/Exclusion Criteria 
 All HIV-positive pregnant women receiving care at the Korle-Bu Fevers Unit and 
Maternity Ward were eligible. Women were ineligible if they were part of other research 
studies, less than 18 years of age, or had hypertension or complications during pregnancy.  




  Part I: Recruitment 
 130 HIV-positive pregnant women in their second or third trimester who were 
eligible were recruited into the study at the Fevers Unit of Korle-Bu Teaching Hospital in 
Accra, Ghana from October 2007 to May 2008 and then again from September 2008 to 
April 2009.  57 subjects were recruited in the 2007-08 period and 74 were recruited in the 
2008-09 period.  
 During the recruitment phase, the subjects were verbally consented and asked a 
series of questions detailed in a questionnaire, utilizing a translator if necessary. Careful 
documentation was made of current or prior treatment and time of diagnosis for both HIV 
and malaria. Blood samples were obtained for initial viral load and CD4 count, and thick 
blood films were prepared for malaria parasitemia analysis.  Finally, a white sticker with 
the research cell phone number and instructions to call if there were any questions was 
placed on the maternity folder.  The subjects were also encouraged to call when they 
went into labor so that the research team could obtain the necessary samples and 
information at delivery. The subjects were then followed prospectively until delivery.  
 124 documented HIV-seronegative pregnant women matched for age (+/-5 years), 
gravity (1,2,3+), parity (0,1,2+), and gestational age (+/- 2 weeks) were recruited at the 
Maternity Ward while waiting for their prenatal appointment. The HIV-negative subjects 
were consented in the same fashion as the HIV-positive subjects and asked to answer the 
same questionnaire. No blood samples were obtained, and the HIV-negative subjects 
were not followed until delivery.  
  Part II: Delivery 




within 48 hours of delivery - one maternal peripheral blood sample for peripheral HIV-1 
RNA viral load testing, one maternal peripheral thick film preparation for peripheral 
malaria parasitemia analysis, and one blood sample from the infant for HIV-1 DNA 
testing. 
 It was common to recruit subjects into the study at the time of delivery as several 
HIV-positive pregnant women had been missed in the initial recruitment phase at the 
Fevers Unit. If the subject had not been recruited prior to delivery, consent was obtained 
and the questionnaire was given to obtain retrospective data. If the subject had been 
previously recruited, follow-up questions regarding antiretroviral initiation, malaria 
exposure and treatment, and additional IPT doses since recruitment were recorded.   
 All HIV-positive women delivering at Korle-Bu Hospital received a dose of 
Nevirapine at the onset of labor. All infants born to HIV-positive women at Korle-Bu 
also received a dose of Nevirapine within 72 hours of birth. According to 2003 WHO 
guidelines on prophylaxis of HIV in infants born to HIV-positive mothers, infants would 
receive additional antiretroviral combination therapy (Combivir) for one week if the 
mother did not start antiretrovirals before 28 weeks gestation, and for 4 weeks if she did 
not receive any antiretroviral therapy prior to delivery. 2  
 Part IIIa: Placental Processing and Examination 
 At delivery, the placenta was obtained and processed within 48 hours.  
Periumbilical and peripheral full-thickness biopsies and membrane samples were taken, 
placed into pencil-labeled cassettes, and fixed in formalin. The formalin-fixed, paraffin-
embedded placental disc tissue, including membranes and umbilical tissue, were then 




immunohistochemistry was also performed on the placental disc according to the 
procedure outlined by Rogerson et al.42 
 Placenta architecture and malaria parasite presence were assessed by a pathologist 
blinded to subject data. Presence of P. falciparum-infected erythrocytes and of malaria 
pigment in fibrin and monocytes was noted. Using a systematic method, 500 intervillous 
blood cells were counted under oil immersion, and classified as uninfected erythrocytes 
(UE), infected erythrocytes (IE), or leukocytes, subdivided by morphology into 
lymphocytes, polymorphs, or monocyte-macrophages. Histologic percentage parasite 
density was defined as IE/(UE + IE), × 100%. 42 Of leukocyte types, only monocyte 
counts varied between infected and uninfected placentas.  A high prevalence of formalin 
pigment precluded assessment of pigment that was due to chronic or past malaria 
infection.  Malaria quantification was performed by parasitologists at The Noguchi 
Institute, a prominent research facility located 45 minutes away from the Korle-Bu 
campus. Parasite densities were calculated by assessing immunohistochemistry placental 
slides at 203 magnification. Five random fields, each of 1 square mm of the placental 
slides, were averaged to obtain density of parasites, expressed as number mm2.42  
  Part IIIb: Blood Sampling and Viral Load Assessment 
 Maternal blood samples were obtained and collected into EDTA tubes. Infant blood 
samples were obtained in the same manner. CD4 assessment was performed at the 
Central Lab of Korle-Bu, through the Fevers Unit. HIV-1 RNA concentration of maternal 
peripheral and placental blood samples were measured using Amplicor HIV-1 Monitor 
version 1.5 (Roche Diagnostics, Branchburg, New Jersey, USA) with a quantification 




 Part IV: HIV-1 DNA testing of infant samples 
 HIV-1 DNA testing of the infant were done using Amplicor HIV-1 Monitor version 
1.5 (Roche Diagnostics, Branchburg, New Jersey, USA). An infant would be considered 
HIV-1 positive and the mother a transmitter if HIV-1 DNA PCR testing was positive 
within 48 hours of delivery, reflecting intrauterine and intrapartum transmission.  
 Thick Film Preparation and Analysis 
 Thick films were prepared from a single drop of blood evenly dispersed in a 2cm-
diameter circle on a microscope slide using a needle tip, then dried overnight in a sealed 
container and stained the next day. Both peripheral and placental thick blood films were 
stained with 20% Giemsa for 10 minutes and examined under oil immersion for malaria 
parasites. The Giemsa was prepared and films stained at the Microbiology Department of 
Korle-Bu. The thick films were then analyzed for malaria parasitemia by two separate 
parasitologists, one at Korle-Bu and one at Noguchi.  A thick film was considered 
negative if 100 microscopic fields showed no parasites.  
  F. Statistical Methods 
 Specific aims 1 and 2a were evaluated using descriptive statistics and chi 
square tests.  Logistic regression was used to determine if placental P. falciparum 
parasitemia was associated with increased peripheral and/or placental HIV-1 RNA 
concentration in HIV-positive women at delivery (Specific Aim 2b).  In the absence of 
data from microscopy or histopathology identifying peripheral or placental malaria 
parasitemia, reported data from the questionnaire of specific aim 1 was utilized as a 
surrogate. Paired, one and two-tailed student t-test statistics were performed on the data 




reporting malaria. The data analyses were conducted using SPSS version 15.0 (SPSS Inc. 
2006). 
 G. Research Personnel  
 My purpose in the project was to continue the work begun by the previous Doris 
Duke Fellow, fine tune the protocol, increase recruitment numbers, conclude the pilot 
study, analyze the data, and assess further areas of research for future collaborations 
between Korle-Bu Teaching Hospital and Yale School of Medicine. I recruited 74 HIV-
positive pregnant women and 84 HIV-negative pregnant women into the study from 
October 2008 to April 2009. Of the HIV-positive subjects, I personally collected and 
processed 32 placentas, 45 maternal peripheral blood samples at delivery, and 15 infant 
blood samples. I improved the attrition rate of placentas from 40% to 15% by the end of 
the research period. I also made thick films at recruitment and delivery for all HIV-
positive subjects that I recruited. I ran the maternal HIV-1 RNA viral load kits for the 
available samples and sampled the placentas of the HIV-positive subjects. I was 
responsible for the day-to-day implementation of the protocol of the pilot study from 
2008-09 and for obtaining cooperation from the staff members of the different 
departments. Finally, I performed the statistical analyses. 
 Viral processing was conducted at the Virology Lab with the assistance of that 
department. Placental processing took place in the Pathology department with the 
assistance of that department. Staining and reading of thick film slides for malaria 
parasitemia took place in the Microbiology department and the Noguchi Institute of 






IV.  RESULTS 
 Part I and Part II of the research project were successfully completed at the 
conclusion of the two-year pilot study. Processing and analysis of data pertaining to Part 
III and Part IV have not yet been completed.  
 A total of 130 HIV-positive subjects were enrolled in the study. 79 delivered at 
Korle-Bu, leaving 51 lost to follow-up (39%). Of the 79 who delivered at Korle-Bu, 
peripheral blood samples were obtained for 60 (76%), placental data was available for 25 
(32%), and infant blood samples were collected for 15 (19%).  
 Table 1 describes the demographic characteristics of the HIV-positive and HIV-
negative subjects. In comparison to their HIV-positive counterparts, the HIV-negative 
subjects were twice as likely to be educated at high school level or beyond (51% vs 
26%), own their own home (36% vs 19%), work in a professional or office setting (24% 
vs 9%), use a flush toilet versus an outside latrine or public toilet (45% vs 23%), and 
have a faucet in the house for water (74% vs 48%).  
  
 
 HIV-1 positive HIV-1 negative P-Value 
 N=130 N=124  
Age (median) 31 (SD 6) 29 (SD 5)  
Level of Education     
           None 21 (16%) 12 (10%)  
           Primary 18 (14%) 15 (12%)  
           Junior Secondary 55 (42%) 60 (48%)  




 HIV-1 positive HIV-1 negative P-Value 
           Secondary and above 34 (26%) 63 (51%) 0.004 
Home     
           Own 25 (19%) 45 (36%) 0.02 
           Rent 78 (60%) 65 (52%)  
           Share 20 (15%) 12 (10%)  
Marital Status    
Married 109 (83%) 106 (85%)  
Single 17 (17%) 16 (15%)  
Occupation    
Professional 5 (4%) 11 (9%) 0.05 
Office 4 (3%) 13 (10%)  
Manual Labor 96 (74%) 82 (66%)  
Unemployed 19 (15%) 17 (14%)  
Sanitation (%)    
           Flush Toilet 20 (23%) 56 (45%) 0.008 
           Pit Latrine in house 14 (11%) 6 (5%)  
           Public Toilet 33 (25%) 22 (18%)  
           Pit Latrine outside  43 (33%) 36 (29%)  
Water (%)    
           Faucet in home 62 (48%) 92 (74%)  
           Outside Home 82 (63%) 20 (16%) <0.0001 
    
 
 Table 2 describes the characteristics of HIV-positive subjects enrolled in the study. 
Among the 130 HIV-positive pregnant women, 64% were diagnosed during the current 




medication prior to or during the current pregnancy, and 42% received only nevirapine at 
labor. The average birth weight of infants born to the HIV-positive subjects was 2.88 kg 
(SD 0.55), and no significant difference in birth weight was found between subjects 
reporting malaria and subjects not reporting malaria (2.80 vs 2.94, p=0.17). CD4 counts 
taken within 6 months of delivery also did not differ between subjects reporting malaria 
and subjects not reporting malaria (408 vs 452, p=0.63).  Of the 13% of subjects whose 
gestational age at delivery was less than 37 weeks, there was no significant difference in 
subjects reporting or not reporting malaria.  
 Also of note, 53% of subjects did not know if their husband or partner was also 
HIV-positive, 18% reported that their husbands or partners had tested negative for HIV, 





CD4 Baseline (median) 423 
  
Diagnosis (%)  
          During current pregnancy 83 (64%) 
          Within year of pregnancy 17 (13%) 
          More than a year before pregnancy 29 (22%) 
Antiretroviral (ARV) Use (%)  
          NVP at labour 53 (41%) 
          Combivir 8 (6%) 
          Combivir and NVP 68 (52%) 





Start of ARVs (%)  
          At labour 55 (42%) 
          At 28 wks gestation or after 35 (27%) 
          Before 28 wks gestation 12 (9%) 
          Before pregnancy 27 (21%) 
Partner HIV-status (%)  
          Unknown 67 (53%) 
          HIV positive 34 (26%) 
          HIV negative 23 (18%) 
Mode of Delivery (%)  
          SVD 43% 
          Elective Caesarian 46% 
          Emergency Caesarian 11% 
GA at Delivery  
>37 weeks 86% 
34-36 weeks 5% 
<34 weeks 8% 
Subjects receiving NVP at onset of labor 100% 
Antiretroviral Prophylaxis of Infants  
NVP 50% 
















 N=130 N=73 N=53  









CD4 Baseline (median) 423 408 359  
ARV Use (%)     
          NVP at labour 53 (41%) 12 (16%) 22 (42%) 0.0006 
          Combivir 8 (6%) 7 (10%) 1 (1%)  
          Combivir and NVP 68 (52%) 51 (70%) 30 (57%)  
GA at Delivery     
>37 weeks 112 (86%) 62 (85%) 47 (86%)  
34-36 weeks 7 (5%) 4 (6%) 2 (4%)  
<34 weeks 10 (8%) 7 (9%) 4 (7%) 0.37 
 
 Table 3 compares malaria characteristics between HIV-positive and HIV-negative 
subjects.  There was no significant difference in reported prevalence of malaria during 
pregnancy between HIV-positive subjects (41%) and HIV-negative subjects (39%). 
Among HIV-positive and HIV-negative subjects, there was no significant difference in 
gravity or parity between subjects reporting malaria and subjects with no malaria reported 
during their pregnancy. There was, however, a lower percentage of HIV-positive women 
receiving more than 2 doses of IPT (23%) compared to HIV-negative women receiving 2 
or more doses (31%), but this was not statistically significant (p=0.55). Among HIV-
positive and HIV-negative groups receiving 2 or more doses of IPT, there was a 
significant difference between the percent of subjects reporting malaria (70% and 71% 
respectively) and subjects not reporting malaria (30% and 28% respectively). See Table 
3b. Likewise, 13% of HIV-positive women reporting malaria received 2 or more doses of 
IPT, whereas 60% received no IPT during pregnancy. No difference was noted in gravity 




or parity among women reporting malaria and not reporting malaria in either the HIV-
positive or HIV-negative populations.  
 In terms of insecticide-treated bednet (ITN) use, over 75% of both HIV-positive 
and HIV-negative groups did not utilize ITNs. But, within the HIV-positive group who 
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39 (81%) 6 (67%) 
 
 
 IPT SP Doses P-value 
HIV-positive 0 1 2  
No Malaria 
Reported 
39 (53%) 13 (18%) 21 (29%)  
Malaria 
Reported 
33 (62%) 13 (25%) 9 (17%) <0.0001 
     
HIV-negative     
No Malaria 
Reported 
32 (43%) 15 (20%) 28 (37%)  
Malaria 
Reported 
20 (42%) 17 (35%) 11 (23%) <0.001 
     
Reported 
Malaria 
    
HIV-positive 33 (62%) 13 (25%) 9 (17%)  
HIV-negative 20 (42%) 17 (35%) 11 (23%) <0.05 
     




 IPT SP Doses P-value 
Hospitalized 
for Malaria 
    
HIV-positive 7 (47%) 6 (40%) 2 (13%)  







 Table 4 shows the relationship between reported malaria infection and HIV-1 RNA 
viral load, both peripheral and placental. At delivery, the overall mean peripheral HIV-1 
viral load was 5045 copies/mL (SD 16014), and mean placental HIV-1 viral load was 
3389 copies/mL (SD 10679). There was no significant difference between HIV-1 RNA 
viral load (either placental or peripheral) in subjects reporting malaria during pregnancy 
and subjects not reporting malaria.   
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 Table 5 shows the relationship of ARV treatment during pregnancy to HIV-1 viral 
load at delivery.  52% of HIV-1 positive women received Combivir and NVP and had 
significantly lower peripheral HIV-1 viral load than the 41% of women who received 
NVP only (8979 copies/ml vs 2131 copies/ml, p=0.05). 
 
 NVP only  (41%) Combivir and NVP  (52%) P value 
HIV-1 Peripheral Viral 
Load (mean) 
8979 copies/ml (SD 22822) 2131 copies/ml (SD 7268) 0.05 
HIV-1 Placental Viral 
Load (mean) 
4154 copies/ml (SD13940) 2956 copies/ml (SD 8552) 0.36 
  
 Information on malaria parasitemia as determined by microscopy for maternal 
Table 5: Relationship of ARV during pregnancy to HIV-1 Viral Load at Delivery 




peripheral and placental thick blood films and histopathological analysis of placental 
samples are not available at this time.   
 
 V.  DISCUSSION 
 This two-year pilot study investigating the role of malaria on HIV-positive 
pregnancy outcomes in Accra, Ghana suggests that, overall, malaria exposure during 
pregnancy does not exacerbate HIV in this population.  HIV-1 RNA viral loads, both 
peripheral and placental, were not significantly different between HIV-positive subjects 
who reported malaria infection and who did not report malaria infection (2914 
copies/mL, 3400 copies/mL vs 6385 copies/mL, 3493 copies/mL, p=0.26, 0.74). 
Prevalence rates of reported malaria among HIV-positive and HIV-negative subjects 
were equivalent (41% and 39%), and though almost twice as many HIV-positive subjects 
reported hospitalization for malaria (12% vs 7%), this was not statistically significant 
(p=0.22).  But though no significant relationship between malaria infection and maternal 
HIV-1 RNA viral load has been established by this study, there are two important 
findings that may influence policy decisions for greater maternal and neonatal risk 
reduction during pregnancy. These two findings are the effect of IPT dosing on reported 
malaria in this population and the effect of combined ARV therapy on HIV-1 RNA viral 
load. These results are not new to the scientific world, but the consistency of these 
findings with previous studies helps to validate the data of this pilot study.  
 With regards to IPT dosing, Table 3b highlights the effectiveness of 2 or more 
doses of IPT on reduction of reported malaria in both HIV-positive (17%) and HIV-




IPT (62% and 42%), (p<0.0001, p<0.001). Between the two populations, though the 
percentage of HIV-negative subjects receiving two or more doses of IPT (31%) was 
higher than the percentage of HIV-positive subjects (23%), this difference was not 
statistically significant (p=0.11). In fact, these rates correlate to National Data for uptake 
of 2 or more doses of IPT among all Ghanaian pregnant women (30%).16 The significant 
effect IPT has on reducing malaria infection in both pregnant populations is reassuring 
and suggests that appropriate policy is in place at present, with the emphasis on reaching 
more HIV-positive pregnant women. Increasing overall access to IPT, however, is 
another challenge.  
 IPT uptake also seems to be the method of malaria prevention that pregnant women 
will more frequently utilize in this study population, but not the only one with positive 
results in the HIV-positive pregnant population. Interestingly, among the HIV-positive 
subjects who utilized ITB, a significant percentage of subjects did not report malaria 
(72%, p<0.0001). This same effect was not seen in the HIV-negative subjects, suggesting 
that the use of ITN should be highly encouraged as part of routine care for HIV-positive 
pregnant women, perhaps to the point of giving a free bednet to every HIV-positive 
pregnant patient. In table 1, HIV-positive pregnant subjects were more likely to have a 
lower socioeconomic status based on occupation, education, and housing options, so it is 
possible that they are exposed more frequently to malaria than their HIV-negative 
counterparts. Thus, it is even more important that ITN use is encouraged during prenatal 
care. Overall, however, only 22% of HIV-positive subjects and 12% of HIV-negative 
subjects reported using ITN. Understanding the reasoning behind such low utilization 




bednets. Providing ITNs, coupled with more aggressive IPT administration, should be the 
preferred antimalarial prevention strategy for HIV-positive pregnant women at Korle-Bu 
Hospital, and perhaps in all of Western Africa.    
 Though this project cannot report on MTCT rates in the research population, data 
from the Korle-Bu Pediatric Department reports the rate of MTCT from 2007-2009 to be 
less than 0.3% (unpublished). As discussed before, risk of MTCT increases 12-fold above 
a HIV RNA viral load of 1,000 copies/mL. The mean peripheral (5045, SD 16 014) and 
placental (3390, SD 10 679) HIV-1 viral loads detected in the pregnant women of this 
project are technically above that cut-off, but the median of both peripheral and placental 
HIV-1 viral loads is less than 400 copies/mL. In fact, 21 of the 28 samples (75%) for both 
peripheral and placental maternal blood have a HIV RNA viral load less than 1000 
copies/mL.  The overall low viral load based on this analysis may be responsible for the 
low rate of MTCT seen in the Korle-Bu Pediatric department. The low viral loads among 
the subjects, in return,  can be attributed to basic access to care and availability of 
antiretrovirals at the Fevers Unit of Korle-Bu Hospital (over 60% of HIV-positive 
subjects received combination therapy prior to delivery and 100% received at least NVP 
at delivery).  The significant difference in peripheral HIV viral load between subjects 
receiving combination therapy prior to delivery and women receiving nevirapine only at 
delivery supports this claim (8979 copies/ml vs 2131 copies/ml, p=0.05). Though the low 
rate of MTCT may suggest that further efforts to reduce risk of MTCT are not needed, 
this should not be the conclusion. Forty percent of HIV-positive women still only receive 
the most basic abbreviated ARV regimen at the biggest teaching hospital in West Africa. 




as even more PMTCT programs should be established to continue to diagnosis 
primigravida women who are unaware of their diagnosis. A startling 60% of women in 
this study were diagnosed with HIV during the current pregnancy, most likely due to 
increased access to testing.   
 Another possible reason for low rates of MTCT in this population may be due to 
the subtype of HIV-1 that predominates in West Africa. There are 9 major subtypes of 
HIV-1 (A,B,C,D,F,G,H,J,K) and 14 major recombinant forms. Epidemiological studies 
have shown that the different subtypes have discrete global distributions.43 For example, 
subtype C accounts for more than 50% of all HIV infections and predominates in Eastern 
and Southern Africa, home to the worst epidemics. Eastern Africa is also home to 
subtype D. Subtype A, on the other hand, is found in West Africa. Several studies have 
suggested that subtypes C and D have higher virulence than subtype A, as subjects with 
subtype C and D developed AIDS faster than subjects with subtype A.44, 45, 46 Recent 
studies have also investigated the association of subtype on MTCT, with heterogenous 
results. The majority showed no association between subtype and rates of MTCT, but two 
studies in East Africa (Kenya and Tanzania) found that subtype A was less transmissible 
than either subtype C or D.47, 48 Therefore, it is possible that subtype is having an effect 
on the low rates of MTCT of HIV-1 among the subjects in this study, but many 
recombinant subtypes may exist in this population, therefore further research would need 
to be done to comment on this relationship. If the HIV subtypes predominating in the 
Accra area are low virulence, this may possibly explain the 18% rate of discordance 
among the HIV-positive pregnant women and their partners. (Table 2) Again, further 




distribution among the HIV-positive pregnant population could add to the understanding 
of another factor influencing MTCT in Ghana.   
 Without analysis of the placental histopathology for malaria parasitemia presence, 
this study cannot definitively speak to the relationship between placental malaria 
parasitemia and HIV-1 viral concentration, both peripheral and placental.  Determining 
placental parasitemia presence, prevalence, and density in the HIV-positive subjects, 
according to histopathological analysis, would further identify the role of malaria in 
pregnancy among Ghanaian women, specifically its effect on MTCT.  Examining the 
local cytokine environment in the placentas of the HIV-positive subjects in this study is 
also an important next step. Particularly in this population of low transmitters, cytokine 
profiles would be very insightful to the interplay between placental malaria and HIV 
transmission. Does it protect or promote MTCT? Is there placental breakdown or, in this 
specific population, does placental malaria parasitemia reduce risk of MTCT of HIV, as 
found by Ayisi et al. 37 
 Though recent studies have discounted the role of increased anti-VSA IgG as a 
protective factor against the adverse maternal and neonatal outcomes of pregnancy-
associated malaria, assessing malaria immunity within this population may be interesting. 
The study found no significant difference in gravity or parity between women who 
reported malaria and women who did not report malaria during their pregnancy, 
irrespective of their HIV-status. While this correlates to previous studies on HIV-positive 
subjects, it is contrary to studies on HIV-negative women.  It is possible that pregnant 
Ghanaian women in this population have a high baseline level of immunity to malaria 




perhaps local cytokine profiles. Assessing levels of this antibody among both HIV-
positive and HIV-negative women could provide further understanding of the role of 
malaria in pregnancy in this population.  
 Whether malaria co-infection increases MTCT of HIV is uncertain in this study, but 
the study clearly shows that proper HIV care, access to combination antiretroviral therapy 
prior to delivery, and protection from malaria infection in pregnancy with ITN and 2 or 
more doses of IPT is of great importance to overall maternal health and reduced vertical 
transmission of HIV.   Efforts must not stand still with regards to providing care to HIV-
positive pregnant women in this population.  
 Limitations, Challenges, and Reflections 
 The project was a collaboration between the OB-GYN Department, the Fevers 
Unit, the Virology Department, the Microbiology Department, and the Pathology 
Department at Korle-Bu Hospital, as well as contributions from The Noguchi Institute 
and Yale School of Medicine. The collaboration was an impressive multidisciplinary 
undertaking in a resource-limited environment that lacked strong intradepartmental 
research infrastructure and history. Though, in practice, communication between all 
departments could have been more extensive, it laid the groundwork for future 
multidisciplinary research projects.  
 There were several limitations to this study that could have affected outcome. The 
first group of limitations involved the research population. The low prevalence of HIV 
among pregnant women in Accra, Ghana provided a small population to assess, even 
over a two-year period. The low numbers of HIV-positive pregnant women limited the 




timing of the project initiation unfortunately coincided with the dry season in Accra 
(October to April) and not the rainy or post-rainy seasons (May to September). It is 
possible that the number of pregnant women reporting malaria in this study would have 
increased if subjects had been enrolled during the rainy season, thus possibly changing 
the results of this study, particularly for the higher socioeconomic HIV-negative 
population, who would have been more exposed to malaria.   
 The second category of limitations, and the major challenge in this study, was the 
limited research budget, and the aspects of the protocol affected by it.   
 Dedicated research personnel were lacking on this project, specifically a dedicated 
translator, labor nurse, parasitologist, OB-GYN resident, and pathologist to assist in the 
collection and processing of data.     
Translation 
 Not having a consistent translator available on the research project meant that 
people unfamiliar with the objectives of the research project or the information to be 
obtained were occasionally used. Significant recall and reporting bias could be affecting 
the current data. 
 Incorrect information from the subjects most likely resulted on many occasions due 
to language and education barrier with the subjects and translators.  A dedicated 
translator would also be able to assist in follow-up of non-English speaking subjects after 
recruitment and during labor.   
Labor Nurse 
  In a project that requires analysis of placental architecture and thick film 




important.  But spending every minute on the labor floor waiting for that placenta is 
infeasible. Having a dedicated labor nurse or team of labor nurses paid to collect and 
immediately process placentas from HIV-positive pregnant women delivering at Korle-
Bu would have increased placental numbers and increased quality of thick film 
preparation of placental blood for microscopy. Though the labor nurses in this project 
received a small stipend for their assistance in procuring HIV-positive placentas, the 
inexperience with research protocol and infrastructure prevented effective contact with 
the main research team when an HIV-positive pregnant woman was ready to deliver. At 
the beginning of the project, there was a high attrition rate of saving the placentas by the 
nurses, but further contact with the labor floor improved those numbers. If more funds 
were available, training could be offered to nurses interested in assisting in the research 
project for a small stipend, widespread knowledge of the project could be conveyed, and 
the protocol could operate more effectively and efficiently. A labor nurse would also 
allow the procurement of HIV-negative placentas matched for age, gravity, parity, 
gestational age, and mode of delivery, allowing a true comparison of placental 
architecture and cytokine environment between HIV-positive and HIV-negative 
pregnancies affected by malaria. This was very difficult to accomplish without nurse 
assistance on the labor floor, and thus it was abandoned early in the project.   
Parasitology 
  The art of the thick film is multilayered, requiring just the right amount of blood, 
just the right thickness. It also requires high quality Giemsa stain and a dedicated 
parasitologist  to stain and read the slides. On the streets of Accra, it is not uncommon to 




slides in this study were stained with this low quality Giemsa. In any malaria study, 
perfecting the procedure for thick film preparation and staining is a necessity, but it is 
also important to have proper training in this, particularly for a researcher unfamiliar with 
this process.      
OB-GYN Resident 
  Though we attempted to utilize the OB-GYN residents as best we could for infant 
blood draws and obstetric chart clarifications, having a dedicated OB-GYN resident as a 
research assistant would help in catching inconsistencies of information reported in the 
chart  (on several occasions, IPT doses had not been documented but the resident 
remembered prescribing) and in difficult infant blood draws. A dedicated OB-GYN 
resident could also assist in identifying both HIV-positive and HIV-negative subjects and 
to inform the rest of the department of ways to assist in the research project. The resident 
could also help in 6 month follow-ups for all subjects who delivered at Korle-Bu to 
assess maternal health, malaria infection postpartum, and infant HIV-conversion. This 
additional data would be very useful, as the effects of pregnancy-associated malaria can 
persist 60 days postpartum. 
  Due to budget restrictions, thick films to test for baseline malaria parasitemia were 
not performed at routine ANC visits. If a women complained of malaria symptoms, she 
received treatment without documentation of parasitemia. Nearly 35% of all pregnant 
women hospitalized for malaria did not have documented thick film assessment, nor 
blood hemoglobin levels (data not presented). Having a dedicated OB-GYN assistant 
familiar with the system to review charts and follow-up on missing information would 





  The last category in this section involves the challenges of conducting a research 
project in a resource-limited setting on a tight research budget, without any prior 
experience. Challenging is the appropriate word. In addition to the budget constraints and 
language barrier, the lack of supplies to process the few samples obtained, and the 
complications of integrating into a foreign hospital infrastructure, the initial unfamiliarity 
with Ghanaian culture stood as the most significant barrier to effective implementation of 
the protocol. I say this because once familiar with the ways of being Ghanaian, assistance 
can readily be found. Of course, it took me 7 of my 8 months to become adept at 
Ghanaian culture, to learn the basics of Twi, the hierarchy of the hospital, the trick to 
infant blood draws, and the way to ensure that placentas from all HIV-positive women 
delivering at Korle-Bu are saved.  
  Research in developing nations such as Ghana remind me of the saying, “It may not 
be the best way or the right way, but it works.” Using broken needles to draw blood from 
the tiny veins of newborn babies and collecting that blood drip by drip in a EDTA tube 
may not be the best way, but it works when butterfly needles are scarce. Reusing gloves 
to process samples over the course of a week is not ideal, but when you need the new 
ones for blood draws on the wards, it works. I am thankful to have experienced that 
version of medicine, a version that is a reality for the majority of people in this world. I 
am thankful to have begun the process of further research into the effect of malaria on 
HIV-positive pregnant women in Accra, Ghana, to have seen, first hand, the vulnerability 
of that population. I am thankful to be a part of research efforts to better understand the 




population through increased access to care, and to stop pregnancy from being the “most 
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